Тест-система для определения наличия связывающих антител к интерферону бета-1а для клинического применения
Резюме
Ключевые слова
Об авторах
Е. А. КузьминоваРоссия
Старший научный сотрудник лаборатории иммунологических методов отдела доклинических испытаний лекарственных средств
Т. Ю. Остроухова
Россия
Руководитель лаборатории иммунологических методов отдела доклинических испытаний лекарственных средств, канд. биол. наук
А. В. Грачев
Россия
Старший научный сотрудник отдела иммунохимии
Е. Л. Морозова
Россия
Руководитель отдела доклинических испытаний лекарственных средств
Список литературы
1. Barnard JG, Babcock K, Carpenter JF. Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity. Journal of Pharmaceutical Sciences 2013; 102(3): 915-28.
2. Mastrangeli R, Rossi M, Mascia M, Palinsky W, Datola A, Terlizzese M, Bierau H. In vitro biological characterization of IFN-β-1a major glycoforms. Glycobiology 2015; 25(1): 21-9.
3. Ahn SH, Lee HW, Kim YS, Kim JK, Han KH, Chon CY, Moon YM. Recombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study. Gut Liver 2009; 3(1): 20-5.
4. Zare N, Zarkesh-Esfahani SH, Gharagozloo M, Shaygannejad V. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon. Journal of Korean Medical Science 2013; 28(12): 1801-6.
5. Gneiss C, Tripp P, Reichartseder F, Egg R, Ehling R, Lutterotti A, Khalil M, Kuenz B, Mayringer I, Reindl M, Berger T, Deisenhammer F. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Journal of Multiple Sclerosis 2006; 12(6): 731-7.
6. Cakal B, Uygunoglu U, Saip S, Altintas A, Siva A, Badur S. BAb and MxA as functional biomarkers in routine clinical laboratories for the determination of anti-IFN-beta antibodies and their bioactivity levels in multiple sclerosis patients. Journal Immunoassay Immunochem 2014; 35(4): 398-411.
7. Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 2003; 61(10): 1444-6.
8. Lapé Nixon M, Matud J, Yeh C, Prince HE. Evaluation of a multiplex bead-based screening assay for detection of binding antibodies to interferon-beta. Journal of Neuroimmunology 2009; 210(1-2): 104-7.
9. White JT, Crossman M, Richter K, Berman M, Goyal J, Subramanyam M. Immunogenicity evaluation strategy for a second-generation therapeutic, PEG-IFN-β-1a. Bioanalysis 2015; 7(21): 2801-11.
10. Ohta M, Ohta K, Ma J, Takeuchi J, Saida T, Nishimura M, Itoh N. Clinical and Analytical Evaluation of an Enzyme Immunoassay for Myelin Basic Protein in Cerebrospinal Fluid. Clinical Chemistry 2000; 46(9): 1326-30.
11. Zoghbi J, Xu J, Grabert R, Theobald V, Richards S. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays. Journal of Immunological Methods 2015; 426: 62-9.
12. Schmidt E, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clinical Immunology 2009; 132(3): 334-41.
13. Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. Journal of Immunological Methods 2005; 304: 189-95.
14. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. Journal of Pharmaceutical and Biomedical Analysis 2008; 48(5): 1267-81.
15. Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf.
Рецензия
Для цитирования:
Кузьминова Е.А., Остроухова Т.Ю., Грачев А.В., Морозова Е.Л. Тест-система для определения наличия связывающих антител к интерферону бета-1а для клинического применения. БИОпрепараты. Профилактика, диагностика, лечение. 2016;16(3):182-188.
For citation:
Kuzminova E.A., Ostroukhova T.Yu., Grachev A.V., Morozova E.L. Test system for the detection of binding antibodies to interferon beta-1a for clinical use. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(3):182-188. (In Russ.)